Latest Posts
About This Stock
More About This Stock
Read
Read
Read
5 Biotech Stocks To Watch As Interest In NASH Increases
Article By:
Arpita Dutt
Thursday, September 22, 2016 1:45 PM EDT
The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH, a common but often “silent” liver disease. Several companies are working on developing treatments for NASH – the market could be worth billions of dollars.
Week In Review: Sorrento Therapeutics Raises $150 Million From China Investors
Article By:
ChinaBio® Today
Saturday, June 11, 2016 7:21 PM EDT
Sorrento Therapeutics (NSDQ: SRNE), a San Diego-China biopharma, closed a $150 million private placement led by Ally Bridge Group, which is headquartered in Hong Kong.
Biotechs With Upside Possibilities Target Ebola And Liver Disease: MLV & Co.'s Vernon Bernardino
Article By:
The Life Sciences Report
Wednesday, September 10, 2014 3:43 PM EDT
In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.